<DOC>
	<DOCNO>NCT00472797</DOCNO>
	<brief_summary>To evaluate impact Quality Life ( QOL ) , tolerability , treatment satisfaction , injection site redness Rebif treat subject relapse form MS transition new formulation Rebif ( RNF ) .</brief_summary>
	<brief_title>Rebif New Formulation ( RNF ) Quality Life ( QOL ) Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Subject relapse form MS ; diagnosis MS accordance McDonald criteria 2 . Subject currently take Rebif 44mcg tiw , treatment least 6 month ( 24 week ) prior study enrollment 3 . Subject currently use Rebiject II 29 gauge needle 4 . Subject 18 60 year old inclusive 5 . Subject able read understand English 6 . Subject willing follow study procedures 7 . Subject give write informed consent sign HIPAA 8 . Female subject must either pregnant breastfeeding must lack childbearing potential , define either : ) Being postmenopausal surgically sterile , ii ) Using hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , duration study . ( Confirmation require within 30 day prior start study ) 1 . Use injectable medication regular basis week prior screening period screen treatment period . Receiving single injection treatment prophylaxis condition unrelated subject 's multiple sclerosis subject 's Rebif® therapy ( e.g. , receive influenza pneumococcus vaccination ) acceptable 2 . Subject receive MS therapy addition ( i.e. , combination therapy ) Rebif® within 3 month prior study enrollment time study protocol . 3 . Subjects previously Rebif New Formulation ( RNF ) . 4 . Subject progressive form Multiple Sclerosis ( MS ) . 5 . Subject history chronic pain syndrome . 6 . Subject disease apart MS could better explain subject sign symptom . 7 . Subject complete transverse myelitis bilateral optic neuritis . 8 . Subjects use investigational drug experimental procedure within 12 week visit 1 . 9 . Subject receive oral systemic corticosteroid ACTH within 30 day visit 1 ( prior enrollment ) . 10 . Subject inadequate liver function , define total bilirubin , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) alkaline phosphatase &gt; 2.5 time upper limit normal value . 11 . Subject inadequate bone marrow reserve , define white blood cell count le 0.5 x low limit normal . 12 . Subject suffers current autoimmune disease . 13 . Subject suffers major medical psychiatric illness opinion investigator create undue risk subject could affect compliance study protocol 14 . Subject pregnant attempt conceive 15 . Visual physical impairment precludes completion diary questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>